- Home
- CRON vs ANAB Comparison
CRON vs ANAB Comparison
Compare CRON & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRON
- ANAB
- Stock Information
- Founded
- CRON N/A
- ANAB 2005
- Country
- CRON Canada
- ANAB United States
- Employees
- CRON N/A
- ANAB N/A
- Industry
- CRON Medicinal Chemicals and Botanical Products
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CRON Health Care
- ANAB Health Care
- Exchange
- CRON Nasdaq
- ANAB Nasdaq
- Market Cap
- CRON 736.2M
- ANAB 621.1M
- IPO Year
- CRON N/A
- ANAB 2017
- Fundamental
- Price
- CRON $2.05
- ANAB $26.94
- Analyst Decision
- CRON
- ANAB Buy
- Analyst Count
- CRON 0
- ANAB 10
- Target Price
- CRON N/A
- ANAB $49.00
- AVG Volume (30 Days)
- CRON 1.4M
- ANAB 526.3K
- Earning Date
- CRON 08-07-2025
- ANAB 08-08-2025
- Dividend Yield
- CRON N/A
- ANAB N/A
- EPS Growth
- CRON N/A
- ANAB N/A
- EPS
- CRON 0.13
- ANAB N/A
- Revenue
- CRON $124,589,000.00
- ANAB $111,872,000.00
- Revenue This Year
- CRON $25.49
- ANAB N/A
- Revenue Next Year
- CRON $7.45
- ANAB $24.39
- P/E Ratio
- CRON $15.93
- ANAB N/A
- Revenue Growth
- CRON 33.92
- ANAB 387.20
- 52 Week Low
- CRON $1.60
- ANAB $12.21
- 52 Week High
- CRON $2.50
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- CRON 53.10
- ANAB 66.30
- Support Level
- CRON $1.99
- ANAB $25.48
- Resistance Level
- CRON $2.15
- ANAB $28.50
- Average True Range (ATR)
- CRON 0.06
- ANAB 1.26
- MACD
- CRON 0.00
- ANAB 0.02
- Stochastic Oscillator
- CRON 35.14
- ANAB 70.23
About CRON Cronos Group Inc. Common Share
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).